Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
2(17%)

Phase Distribution

Ph phase_3
2
17%
Ph phase_1
2
17%
Ph phase_4
1
8%
Ph early_phase_1
1
8%
Ph not_applicable
6
50%

Phase Distribution

3

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
2(16.7%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
1(8.3%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(6)
Terminated(2)
Other(4)

Detailed Status

Completed6
unknown4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 12 (16.7%)
Phase 32 (16.7%)
Phase 41 (8.3%)
N/A6 (50.0%)

Trials by Status

terminated217%
unknown433%
completed650%

Recent Activity

0 active trials
Showing 5 of 12
unknownphase_3

Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

NCT03800524
completedphase_1

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

NCT03423121
unknownphase_3

Open Label Extension of TUDCA-ALS Study

NCT05753852
terminatednot_applicable

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
unknownearly_phase_1

The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

NCT04727320
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT03800524Phase 3

Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

Unknown
NCT03423121Phase 1

A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis

Completed
NCT05753852Phase 3

Open Label Extension of TUDCA-ALS Study

Unknown
NCT03462940Not Applicable

Effects of TUDCA on Endothelial Function in Type 2 DM

Terminated
NCT04727320Early Phase 1

The Clinical Application of Tauroursodeoxycholic Acid in Patients With Liver Fibrosis.

Unknown
NCT01877551Not Applicable

Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance

Completed
NCT03878654Phase 1

Trial of Tauroursodeoxycholic Acid (TUDCA) in Asthma

Terminated
NCT00771901Not Applicable

Effect of Endoplasmic Reticulum Stress on Metabolic Function

Completed
NCT03331432Not Applicable

Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function

Completed
NCT01998451Phase 4

The Discovery of the Double Sphincter in Gallbladder

Unknown
NCT00004441Not Applicable

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

Completed
NCT00004410Not Applicable

Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants

Completed

All 12 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
12